Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesLSE:RUA +4.35%47 FCF Margin % is -29.09% as of Mar. 2026. GuruFocus rates LSE:RUA with a GF Score™ of 47/100 and a GF Value™ of £0.17 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, RUA Life Sciences ranks worse than 74.26% on this metric.
The historical rank and industry rank for RUA Life Sciences's FCF Margin % or its related term are showing as below:
LSE:RUA'
s FCF Margin % Range Over the Past 10 Years
Min: -200.43 Med: -68.16 Max: 81.93
Current: -29.09
During the past 13 years, the highest FCF Margin % of RUA Life Sciences was 81.93%. The lowest was -200.43%. And the median was -68.16%.
LSE:RUA's FCF Margin % is ranked worse than 74.26% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: -0.55
vs LSE:RUA: -29.09
RUA Life Sciences FCF Margin % Related Terms
RUA Life Sciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, RUA Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (LSE:RUA) has a FCF Margin % of -29.09% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RUA Life Sciences and its competitors. According to the industry distribution chart, RUA Life Sciences ranks #606 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 74.3%.
Is RUA Life Sciences' FCF Margin % too high?
RUA Life Sciences' current FCF Margin % is -29.09%. Based on the distribution chart, RUA Life Sciences ranks #606 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, RUA Life Sciences has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #606 out of 816 companies for FCF Margin %. This places RUA Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RUA Life Sciences and its competitors. RUA Life Sciences's current FCF Margin % is -29.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (LSE:RUA) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.17, compared to a current price of £0.24 — trading 41.2% above its estimated fair value. The current FCF Margin % is -29.09%. RUA Life Sciences' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For RUA Life Sciences (LSE:RUA), the current FCF Margin % is -29.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (LSE:RUA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of £0.24 is trading 41.2% above its estimated GF Value™ of £0.17.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for LSE:RUA:
FCF Margin %: -29.09%
GF Value™: £0.17 vs. price of £0.24 (41.2% above fair value)
No single metric tells the full story. See the LSE:RUA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
47GF Score
Get the complete analysis for LSE:RUA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RUA has been successfully added to your 
